NAD+ vs Nasal Spray: Comparing the Indexed Record
Before NAD+ and Nasal Spray can be compared on anything else, they have to be compared on evidence: what has actually been indexed, and where.
Compound profiles
NAD+ in the indexed record
Searching NAD+ against the PubMed index returns 76,583 records, an extensive evidence base, alongside 749 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Cell Metab, EMBO Mol Med, Nat Metab, spanning 2020–2024.
- NAD(+) metabolism and its roles in cellular processes during ageing — Nat Rev Mol Cell Biol, 2021. PMID: 33353981
- NAD(+) metabolism, stemness, the immune response, and cancer — Signal Transduct Target Ther, 2021. PMID: 33384409
- NAD(+) homeostasis in health and disease — Nat Metab, 2020. PMID: 32694684
- NAD(+) homeostasis in human health and disease — EMBO Mol Med, 2021. PMID: 34041853
Nasal Spray in the indexed record
Nasal Spray returns 4,133 indexed records on PubMed, a substantial record, alongside 1,589 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Am J Cardiovasc Drugs, Drug Ther Bull, Expert Rev Neurother, spanning 2019–2024.
- Development of neffy, an Epinephrine Nasal Spray, for Severe Allergic Reactions — Pharmaceutics, 2024. PMID: 38931932
- Naloxone nasal spray — Drug Ther Bull, 2019. PMID: 31296655
- Budenoside aqueous nasal spray: an updated reappraisal in rhinitis management — Minerva Med, 2024. PMID: 38414250
- Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults — Expert Rev Neurother, 2024. PMID: 38655598
How the literature differs
The indexed record is not symmetrical between these two compounds. NAD+ carries 72,450 more indexed records than Nasal Spray, which means published methodology, characterisation data and replication attempts are more readily located for NAD+. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (749 vs 1,589) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | NAD+ | Nasal Spray |
|---|---|---|
| PubMed indexed records | 76,583 | 4,133 |
| Registered studies (ClinicalTrials.gov) | 749 | 1,589 |
| Literature depth | Extensive | Extensive |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
NAD+ and Nasal Spray sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for NAD+ describes conditions validated for NAD+: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Nasal Spray without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Frequently asked questions
Are NAD+ and Nasal Spray the same compound?
No. They are structurally distinct research compounds with separate literature records — 76,583 indexed records for NAD+ and 4,133 for Nasal Spray.
Which of NAD+ or Nasal Spray has more published research?
NAD+, with 76,583 indexed PubMed records against 4,133.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Related references
- NAD+ — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.